Jacobs Levy Equity Management Inc. Lowers Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Jacobs Levy Equity Management Inc. reduced its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) by 81.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 18,951 shares of the company’s stock after selling 84,489 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in TScan Therapeutics were worth $58,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of TCRX. Barclays PLC boosted its position in shares of TScan Therapeutics by 341.1% during the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock worth $289,000 after buying an additional 44,903 shares during the period. JPMorgan Chase & Co. boosted its position in shares of TScan Therapeutics by 94.4% during the third quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company’s stock worth $158,000 after buying an additional 15,441 shares during the period. SG Americas Securities LLC boosted its position in shares of TScan Therapeutics by 31.2% during the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after buying an additional 4,852 shares during the period. Heck Capital Advisors LLC purchased a new position in shares of TScan Therapeutics during the fourth quarter worth $61,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of TScan Therapeutics during the fourth quarter worth $32,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Stock Down 5.3%

TScan Therapeutics stock opened at $1.24 on Monday. TScan Therapeutics, Inc. has a 1-year low of $1.02 and a 1-year high of $9.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The stock has a market cap of $70.17 million, a PE ratio of -1.17 and a beta of 1.06. The stock’s fifty day moving average is $1.43 and its two-hundred day moving average is $2.57.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The company had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.62 million. On average, sell-side analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on TCRX. Barclays lowered their price target on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Morgan Stanley reiterated an “overweight” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research note on Friday, March 14th. Wedbush reiterated an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Finally, HC Wainwright reduced their price objective on TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $7.80.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.